Cogent Biosciences, Inc.
COGT
주식 순위
#3232
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
주가
$31.49
마지막 동기화: 2026-10-21
시가총액
$5.46B
변동 (1일)
0.81%
변동 (1년)
112.08%
국가
US
거래 Cogent Biosciences, Inc. (COGT)
카테고리
Healthcare
Cogent Biosciences, Inc. (COGT)의 주가 이력
최고 종가: $30.19 (2026-10-01 기준)
최저 종가: $44.44 (2018-03-01 기준)
최저 종가: $44.44 (2018-03-01 기준)
Cogent Biosciences, Inc.의 주가 이력 (2018 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.77 | -3.82% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
